Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (nivolumab)
Time to recurrence · stage III and IV cutaneous melanoma
1 finding from 1 review
- Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes onlyno estimate extracted1 study · 23 participantsLow